BMA
Banco Macro S.A.
There isn't enough reported data to score BMA yet.
GS
The Goldman Sachs Group, Inc.
GS's fundamentals are strong: revenue grew 19% and its operating margin rose 4 points to 40%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| N/A | |
| N/A |
BMA's profitability is currently stable. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like BMA.
GS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
GS's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like GS.
BMA PE Valuation
BMA has no meaningful PE right now: it lost money over the past year.
GS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.6x | $528 | -42% |
| Current | 13x | $914 | — |
| Forward | 13x | $914 | — |
| Fair | 14x | $940 | +2.9% |
| Expensive | 17x | $1,214 | +33% |
Historical ranges are pointers, not guarantees.
GS's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for BMA, with profitability improving.
GS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GS, with profitability improving. However, they disagree widely on these estimates.
BMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | $2.98 | -59% |
| Q2 2025 | $4.23 | -35% |
| Q1 2025 | -$0.48 | -104% |
| Q4 2024 | $3.45 | -51% |
| Q3 2024 | $7.21 | +226% |
| Q2 2024 | $6.52 | +198% |
| Q1 2024 | $11.38 | +1735% |
| Q4 2023 | $7.10 | +1009% |
GS has the stronger earnings trend. Trailing diluted EPS is down 59% for BMA versus GS up 41%.
GS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $72.35 | +4% |
| Q3 2026 | $69.58 | +41% |
| Q2 2026 | $64.82 | +43% |
| Q1 2026 | $54.75 | +27% |
| Q4 2025 | $51.32 | +27% |
| Q3 2025 | $49.22 | +44% |
| Q2 2025 | $45.37 | +45% |
| Q1 2025 | $43.08 | +68% |
| Q4 2024 | $40.54 | +77% |
GS's earnings per share have climbed steadily: $69.58 over the past year, up 41% from the year before, and higher year over year for 10 quarters in a row. Its recent earnings include one-off gains.
BMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $950.1M | +4.1% |
| Q1 2026 | $1.2B | +70% |
| Q3 2025 | $933.9M | +30% |
| Q2 2025 | $912.7M | +16% |
| Q1 2025 | $725M | -66% |
| Q4 2024 | $970.7M | -44% |
| Q3 2024 | $719.9M | -46% |
| Q2 2024 | $789.5M | -29% |
BMA has the stronger quarterly revenue trend. Revenue is up 31% for BMA versus up 23% for GS.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 22% | +15 points |
| Q1 2026 | 11% | -0.1 points |
| Q3 2025 | -2.6% | -14 points |
| Q2 2025 | 17% | +59 points |
| Q1 2025 | 7.2% | -10 points |
| Q4 2024 | 11% | -17 points |
| Q3 2024 | 11% | +8 points |
| Q2 2024 | -41% | -55 points |
BMA's operating margin was 22% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
GS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7B | +23% |
| Q2 2026 | $20.3B | +39% |
| Q1 2026 | $17.2B | +14% |
| Q4 2025 | $13.5B | -3% |
| Q3 2025 | $15.2B | +20% |
| Q2 2025 | $14.6B | +15% |
| Q1 2025 | $15.1B | +6% |
| Q4 2024 | $13.9B | +23% |
GS's revenue is growing: $18.7B last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +2 points |
| Q2 2026 | 42% | +8.1 points |
| Q1 2026 | 38% | +0.2 points |
| Q4 2025 | 44% | +5.6 points |
| Q3 2025 | 36% | +4.1 points |
| Q2 2025 | 34% | +3.2 points |
| Q1 2025 | 37% | +0.6 points |
| Q4 2024 | 38% | +18 points |
GS has the edge over BMA on profitability, with a higher operating margin.
BMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $372.3M | +$984.4M |
| Q1 2026 | $384.5M | +$1B |
| Q3 2025 | $304.5M | -63% |
| Q2 2025 | -$612.1M | -271% |
| Q1 2025 | -$616.8M | -10886964% |
| Q4 2024 | -$353.2M | -$232.5M |
| Q3 2024 | $818.8M | +$896.2M |
| Q2 2024 | $357M | +$365.4M |
BMA has the stronger cash trend. Its trailing FCF is up 207% versus its history, compared with GS at down 278%.
GS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +72% |
| Q2 2026 | $5.6B | +7.8% |
| Q1 2026 | -$32.4B | +$5.3B |
| Q4 2025 | -$16.8B | -136% |
| Q3 2025 | $2.1B | +$40.6B |
| Q2 2025 | $5.2B | -6.8% |
| Q1 2025 | -$37.7B | -$9.2B |
| Q4 2024 | $46.2B | +$75.1B |
GS's free cash flow was −$40B over the past year, against $15.8B the year before. Free cash flow isn't a meaningful measure for financial services companies like GS.
BMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -38K shares |
| 1 year | -0.1% | -40.3K shares |
| 3 years | -0.1% | -40.3K shares |
| 5 years | -1.2% | -804K shares |
| Available history | -0.1% | -38.8K shares |
BMA has 64M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
GS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -3.8M shares |
| 1 year | -4.4% | -13.9M shares |
| 3 years | -12% | -42.8M shares |
| 5 years | -15% | -52.8M shares |
| Available history | -20% | -74.4M shares |
GS has the edge over BMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3B |
| Q2 2026 | $4B |
| Q1 2026 | $5B |
| Q4 2025 | $3B |
| Q3 2025 | $2B |
| Q2 2025 | $3B |
| Q1 2025 | $4.4B |
| Q4 2024 | $2B |
GS spent $15B buying back its own shares over the past year, up 32% from the year before.
BMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -3.1x | Net Cash |
| Q2 2025 | -2.0x | Net Cash |
| Q1 2025 | -57.5x | Net Cash |
| Q4 2024 | -4.4x | Net Cash |
| Q3 2024 | -2.8x | Net Cash |
| Q2 2024 | -1.3x | Net Cash |
| Q1 2024 | -0.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
BMA has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BMA.
GS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.4x | Net Cash |
| Q2 2026 | -6.1x | Net Cash |
| Q1 2026 | -6.7x | Net Cash |
| Q4 2025 | -6.4x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2025 | -3.1x | Net Cash |
| Q1 2025 | -3.9x | Net Cash |
| Q4 2024 | -4.7x | Net Cash |
GS has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like GS.
BMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 4.0 | Oversold |
BMA's weekly RSI is 33 (neutral) and its Stochastic is 4 (oversold).
GS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 16.3 | Oversold |
GS's weekly RSI is 45 (neutral) and its Stochastic is 16 (oversold).
BMA PE vs Financial Services Sector
BMA has no meaningful PE right now: it lost money over the past year.
GS PE vs Financial Services Sector
| Metric | GS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.8% above |
| PE % | 46 | 63 | 17 pts below |
GS is trading at 13x earnings, in line with the Financial Services sector's median of 13x, though its earnings don't support one.
BMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.7 | 12% below |
| 20 week MA | $75.0 | 26% below |
| 50 week MA | $80.5 | 31% below |
| 100 week MA | $79.3 | 30% below |
| 200 week MA | $59.4 | 6.9% below |
BMA is in a downtrend: it's below all five of its weekly moving averages, and 6.9% below its 200-week average.
GS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $895.5 | 2% above |
| 20 week MA | $977.4 | 6.5% below |
| 50 week MA | $945.4 | 3.4% below |
| 100 week MA | $804.5 | 14% above |
| 200 week MA | $602.7 | 52% above |
GS has the edge over BMA on trend strength, trading above more of its moving averages.
BMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.4 | $15.6 | -57% |
| 2021 | $15.6 | $14.6 | -6.6% |
| 2022 | $14.6 | $15.8 | +8.9% |
| 2023 | $15.8 | $28.7 | +81% |
| 2024 | $28.7 | $100.2 | +249% |
| 2025 | $100.2 | $91.4 | -8.8% |
| 2026 YTD | $91.4 | $55.2 | -40% |
BMA's yearly returns have swung widely, from +249% in 2024 to −57% in 2020. It's down 40% so far in 2026.
GS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $230.7 | $256.2 | +11% |
| 2021 | $256.2 | $385.0 | +50% |
| 2022 | $385.0 | $345.5 | -10% |
| 2023 | $345.5 | $385.8 | +12% |
| 2024 | $385.8 | $576.2 | +49% |
| 2025 | $576.2 | $907.0 | +57% |
| 2026 YTD | $907.0 | $913.6 | +0.7% |
GS has the edge over BMA on returns for 2026, with the stronger performance.